15 Stocks with Buy Ratings that Hedge Funds Love

Page 7 of 13

7. Zoetis Inc. (NYSE:ZTS)

No. of Hedge Funds: 76

Value of the hedge funds: $2.46 billion

Zoetis Inc. (NYSE:ZTS) is a global leader in animal health. Headquartered in New Jersey, the company manufactures vaccines, medicines, diagnostics, and genetics products for pets and livestock. Zoetis serves veterinarians, farmers, and pet owners in over 100 countries and uses decades of research to find solutions for emerging diseases. Against tough competitors like Elanco, the company obtains market through its strong innovation engine and digital tools for animal health monitoring and precision care.

Zoetis Inc. (NYSE:ZTS) has attracted strong hedge fund backing, with 76 funds holding $2.46 billion in shares, according to Insider Monkey’s Q4 2024 database. A strong demand for the products in 2024 enabled the company to achieve a double-digit operational revenue growth of 11%. The Simparica and OA pain franchises contributed to a 14% increase in revenue in the companion animal portfolio of Zoetis. The newly launched Librela in the U.S. also positively affected the revenue. Much of the positive expectations for the company are centered around its guidance for 2025, which anticipates revenue between $9.225 billion and $9.375 billion.

Zoetis Inc. (NYSE:ZTS)’s EPS for the past five years has grown by 11.91%, indicating elevated business and financial performance. The growth further reinforces analysts’ confidence, managing to secure a Strong Buy rating for the stocks.

Page 7 of 13